-+ 0.00%
-+ 0.00%
-+ 0.00%

Basilea provides portfolio update and outlook

Barchart·01/08/2026 00:15:00
語音播報

Allschwil, Switzerland, January 08, 2026

Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, reported today on the progress within its R&D and commercial portfolio during 2025 and outlined the upcoming milestones and timelines.

Read more at globenewswire.com

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.